caa a22 4500 605543542 CHVBK 20210128100927.0 cr unu---uuuuu 210128e20151001xx s 000 0 eng 10.1007/s00109-015-1326-7 doi (NATIONALLICENCE)springer-10.1007/s00109-015-1326-7 mTOR in health and in sickness [Elektronische Daten] [Dritan Liko, Michael Hall] Target of rapamycin (TOR) is a highly conserved protein kinase that plays a key role in mediating cell growth and homeostasis. It is activated by nutrients, growth factors, and cellular energy levels to control a number of anabolic and catabolic processes. It is a validated drug target implicated in a variety of diseases. In this review, we describe the molecular mode of action of TOR in the context of cellular and organismal physiology. We focus on mammalian TOR (mTOR) signaling in cancer and neurological disease and discuss usage of TOR inhibitors in the clinic. Springer-Verlag Berlin Heidelberg, 2015 mTOR nationallicence Health nationallicence TOR nationallicence mTORC1 nationallicence mTORC2 nationallicence mTOR inhibitors nationallicence Rapamycin nationallicence Rapalogs nationallicence Disease nationallicence Liko Dritan Biozentrum, University of Basel, 4056, Basel, Switzerland aut Hall Michael Biozentrum, University of Basel, 4056, Basel, Switzerland aut Journal of Molecular Medicine Springer Berlin Heidelberg 93/10(2015-10-01), 1061-1073 0946-2716 93:10<1061 2015 93 109 https://doi.org/10.1007/s00109-015-1326-7 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 review-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00109-015-1326-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Liko Dritan Biozentrum, University of Basel, 4056, Basel, Switzerland aut NATIONALLICENCE 700 1- Hall Michael Biozentrum, University of Basel, 4056, Basel, Switzerland aut NATIONALLICENCE 773 0- Journal of Molecular Medicine Springer Berlin Heidelberg 93/10(2015-10-01), 1061-1073 0946-2716 93:10<1061 2015 93 109